Spots Global Cancer Trial Database for hypomethylating agents
Every month we try and update this database with for hypomethylating agents cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | NCT04589728 | Acute Myeloid L... | Venetoclax plus... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) | NCT02929498 | Myelodysplastic... Myelodysplastic... | GSK2879552 Azacitidine | 18 Years - | GlaxoSmithKline | |
| Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | NCT04589728 | Acute Myeloid L... | Venetoclax plus... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | NCT03946670 | Myelodysplastic... | MBG453 Placebo Hypomethylating... | 18 Years - | Novartis | |
| Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome | NCT04999943 | Myelodysplastic... Dendritic Cell Hypomethylating... Immunotherapy | DC vaccine | 60 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| Combining Active and Passive DNA Hypomethylation | NCT03999723 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... | Vitamin C Placebo | 18 Years - | Rigshospitalet, Denmark | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome | NCT04999943 | Myelodysplastic... Dendritic Cell Hypomethylating... Immunotherapy | DC vaccine | 60 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy | NCT04454580 | Acute Myeloid L... Hypomethylating... Venetoclax | Venetoclax | 18 Years - | Ospedale Maggiore Di Trieste |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
